Development and testing of in vitro companion assay for novel hypoxia-activated mitochondrial prodrugs****

新型缺氧激活线粒体前药的体外伴随测定的开发和测试****

• 批准号: 536832-2018
• 负责人: Karshafian, Raffi
• 金额: $ 1.82万
• 依托单位: Ryerson University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=655150
• 关键词: Development; testing; vitro; companion; assay

Cyclica has developed a new technology, termed Differential Drug Discovery (DDD), to design single molecules capable of targeting multiple proteins simultaneously and retain drug like characteristics. The project will design tumour specific pro-drugs to target mitochondrial respiration. To achieve this Cyclica software developers must design constructs to predict chemical structures that will target various proteins in the mitochondria. Our team will develop a companion assay to test the novel chemical structures designed in the software and substantiate the computer aided predictions. We will perform optimization, benchmarking and assays required for Cyclica to proceed to the commercialization of the novel computational drug discovery application of their AI technology.**

Cyclica开发了一种名为差异药物发现（DDD）的新技术，用于设计能够同时靶向多种蛋白质并保留药物特征的单分子。该项目将设计针对线粒体呼吸的肿瘤特异性前药。为了实现这一目标，Cyclica软件开发人员必须设计结构来预测线粒体中各种蛋白质的化学结构。我们的团队将开发一个配套的分析来测试软件中设计的新化学结构，并证实计算机辅助预测。我们将进行Cyclica所需的优化，基准测试和分析，以继续将其AI技术的新型计算药物发现应用商业化。